Literature DB >> 22971798

Regulation of glucose transporter protein-1 and vascular endothelial growth factor by hypoxia inducible factor 1α under hypoxic conditions in Hep-2 human cells.

Ou Xu1, Xiaoming Li, Yongtao Qu, Shuang Liu, Jie An, Maoxin Wang, Qingjia Sun, Wen Zhang, Xiuying Lu, Lihong Pi, Min Zhang, Yupeng Shen.   

Abstract

The present study evaluated the regulation of glucose transporter protein-1 (Glut-1) and vascular endothelial growth factor (VEGF) by hypoxia inducible factor 1α (HIF-1α) under hypoxic conditions in Hep-2 human cells to explore the feasibility of these three genes as tumor markers. Hep-2 cells were cultured under hypoxic and normoxic conditions for 6, 12, 24, 36 and 48 h. The proliferation of Hep-2 cells was evaluated using an MTT assay. The protein and mRNA expression levels of HIF-1α, Glut-1 and VEGF were detected using the S-P immunocytochemical method, western blotting and reverse transcription polymerase chain reaction (RT-PCR). The results revealed that the expression levels of HIF-1α, Glut-1 and VEGF protein in Hep-2 cells were significantly elevated under hypoxic conditions compared with those under normoxic conditions over 36 h. Under hypoxic conditions, mRNA levels of HIF-1α were stable, while mRNA levels of Glut-1 and VEGF changed over time. In conclusion, Glut-1 and VEGF were upregulated by HIF-1α under hypoxic conditions in a time-dependent manner in Hep-2 cells and their co-expression serves as a tumor marker.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22971798     DOI: 10.3892/mmr.2012.1075

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  5 in total

1.  Early and Late Histological and Ultrastructural Findings in Resected Infantile Capillary Hemangiomas Following Treatment with Topical Beta-Blocker Timolol Maleate 0.5.

Authors:  Zuzana Sipkova; Kanmin Xue; Hardeep S Mudhar; Bart Wagner; Göran Darius Hildebrand
Journal:  Ocul Oncol Pathol       Date:  2017-08-23

2.  Study protocol: safety and efficacy of propranolol 0.2% eye drops in newborns with a precocious stage of retinopathy of prematurity (DROP-ROP-0.2%): a multicenter, open-label, single arm, phase II trial.

Authors:  Luca Filippi; Giacomo Cavallaro; Elettra Berti; Letizia Padrini; Gabriella Araimo; Giulia Regiroli; Valentina Bozzetti; Chiara De Angelis; Paolo Tagliabue; Barbara Tomasini; Giuseppe Buonocore; Massimo Agosti; Angela Bossi; Gaetano Chirico; Salvatore Aversa; Roberta Pasqualetti; Pina Fortunato; Silvia Osnaghi; Barbara Cavallotti; Maurizio Vanni; Giulia Borsari; Simone Donati; Giuseppe Nascimbeni; Giancarlo la Marca; Giulia Forni; Silvano Milani; Ivan Cortinovis; Paola Bagnoli; Massimo Dal Monte; Anna Maria Calvani; Alessandra Pugi; Eduardo Villamor; Gianpaolo Donzelli; Fabio Mosca
Journal:  BMC Pediatr       Date:  2017-07-14       Impact factor: 2.125

3.  The Rho/Rac Guanine Nucleotide Exchange Factor Vav1 Regulates Hif-1α and Glut-1 Expression and Glucose Uptake in the Brain.

Authors:  Jaewoo Hong; Yurim Kim; Sudhirkumar Yanpallewar; P Charles Lin
Journal:  Int J Mol Sci       Date:  2020-02-17       Impact factor: 5.923

Review 4.  Role of hypoxia preconditioning in therapeutic potential of mesenchymal stem-cell-derived extracellular vesicles.

Authors:  Victoria Pulido-Escribano; Bárbara Torrecillas-Baena; Marta Camacho-Cardenosa; Gabriel Dorado; María Ángeles Gálvez-Moreno; Antonio Casado-Díaz
Journal:  World J Stem Cells       Date:  2022-07-26       Impact factor: 5.247

Review 5.  Metabolomics in rheumatoid arthritis: Advances and review.

Authors:  Lingxia Xu; Cen Chang; Ping Jiang; Kai Wei; Runrun Zhang; Yehua Jin; Jianan Zhao; Linshuai Xu; Yiming Shi; Shicheng Guo; Dongyi He
Journal:  Front Immunol       Date:  2022-08-11       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.